BridgeBio Pharma (BBIO) Non Operating Income (2018 - 2026)
BridgeBio Pharma (BBIO) posted Non Operating Income of -$60.6 million for Q1 2026, down 9.79% sequentially from -$55.2 million in Q4 2025, and up 7.11% YoY from -$56.6 million in Q1 2025.
BridgeBio Pharma (BBIO) Non Operating Income (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported Non Operating Income for 9 years, with the latest figure at -$60.6 million in Q1 2026.
- Quarterly Non Operating Income rose 7.11% year-over-year to -$60.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$204.5 million (down 1027.4% YoY) and the FY2025 annual result came in at -$209.1 million, down 511.77% from the prior year.
- Non Operating Income slipped to -$60.6 million in Q1 2026 per BBIO's latest filing, from -$55.2 million in the prior quarter.
- Over five years, Non Operating Income peaked at $100.0 million in Q2 2024 and troughed at -$65.2 million in Q1 2025.
- A 5-year average of -$14.0 million and a median of -$21.8 million in 2023 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 1063.11% in 2022, down 672.83% in 2022.
- Over 5 years, Non Operating Income stood at -$11.3 million in 2022, then soared by 162.52% to $7.1 million in 2023, then slumped by 667.28% to -$40.2 million in 2024, then slumped by 37.27% to -$55.2 million in 2025, then retreated by 9.79% to -$60.6 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$60.6 million, -$55.2 million, and -$41.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | -48.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.81 Mn |
| Mar 31, 2026 | -60.60 Mn |
| Dec 31, 2025 | -55.19 Mn |
| Sep 30, 2025 | -41.28 Mn |
| Jun 30, 2025 | -47.38 Mn |
| Mar 31, 2025 | -65.24 Mn |
| Dec 31, 2024 | -40.21 Mn |
| Sep 30, 2024 | 27.50 Mn |
| Jun 30, 2024 | 100.00 Mn |
| Mar 31, 2024 | -36.50 Mn |
| Dec 31, 2023 | 7.09 Mn |
| Sep 30, 2023 | -21.80 Mn |
| Jun 30, 2023 | -14.60 Mn |
| Mar 31, 2023 | -16.57 Mn |
| Dec 31, 2022 | -11.34 Mn |
| Sep 30, 2022 | -11.08 Mn |
| Jun 30, 2022 | 77.62 Mn |
| Mar 31, 2022 | -27.65 Mn |
| Dec 31, 2021 | 13.33 Mn |
| Sep 30, 2021 | -11.52 Mn |